Klinische Studien
Early University of Calgary trial tests high-dose niacin as add-on treatment for glioblastoma
Von KI berichtet Bild generiert von KI Fakten geprüft
Researchers at the University of Calgary are studying whether high doses of vitamin B3 (niacin) can improve outcomes for patients with newly diagnosed glioblastoma when added to standard treatment. An interim analysis of 24 patients found a higher-than-expected six‑month progression‑free survival rate, though investigators stress the results are preliminary and require ongoing safety monitoring.
A new experimental oral medication called elecoglipron improved blood sugar control and promoted weight loss in adults with type 2 diabetes during a phase 2b trial. Results from the SOLSTICE study were presented at the American Diabetes Association's Scientific Sessions and published in The Lancet.
Von KI berichtet
A new treatment called Daraxonrasib has shown strong results against advanced pancreatic cancer in a recent clinical trial. The drug targets a genetic mutation long considered impossible to treat effectively.
Takeda Pharmaceutical has announced that its AI-assisted oral psoriasis drug zasocitinib proved safe and effective in late-stage trials. The once-daily pill outperformed placebo and the existing therapy apremilast in clearing skin for patients with moderate-to-severe plaque psoriasis. If approved, it would mark one of the first drugs discovered with artificial intelligence.
Von KI berichtet
Ein experimenteller Nasenspray-Impfstoff hat erstmals die Kolonisierung von Keuchhusten-Bakterien beim Menschen verhindert, so eine kürzlich veröffentlichte klinische Studie. Dieser Durchbruch könnte die Ausbreitung der Krankheit eindämmen, insbesondere in einem Jahr mit Rekordfällen in England. Der BPZE1-Impfstoff von ILiAD Biotechnologies reduzierte das Vorhandensein von Bakterien um über 97 % im Vergleich zu Placebo.
A combination of enzalutamide and hormone therapy has reduced the risk of death by more than 40% in men with recurring prostate cancer, according to a major clinical trial. The study, involving over 1,000 patients worldwide, was led by researchers at Cedars-Sinai and presented at a medical congress in Berlin. Experts describe the findings as a game changer for treating aggressive cases.
Von KI berichtet
The U.S. Food and Drug Administration has finalized a rule requiring drug sponsors to submit diversity action plans for clinical trials. This aims to ensure better representation of underrepresented groups in medical research. The rule takes effect in 2025.
Virus injection halts pancreatic tumor growth in trial
Donnerstag, 28. Mai 2026, 16:21 UhrGene-editing drug slashes bad cholesterol 62 percent in trial
Montag, 25. Mai 2026, 16:39 UhrStudy finds beta blockers offer no benefit after uncomplicated heart attacks
Sonntag, 17. Mai 2026, 08:37 UhrTenaya Therapeutics publishes RIDGE-1 data on TN-401 gene therapy
Dienstag, 12. Mai 2026, 11:26 UhrIntellia reports strong phase iii results for hae treatment
Samstag, 22. November 2025, 02:26 UhrStem cell therapy restores vision in AMD patients
Donnerstag, 13. November 2025, 04:09 UhrCheap gout drug colchicine may prevent heart attacks and strokes
Donnerstag, 06. November 2025, 13:09 UhrOral semaglutide pill yields up to 16.6% weight loss in NEJM obesity trial
Mittwoch, 22. Oktober 2025, 20:00 UhrWegovy provides heart benefits even with minimal weight loss
Montag, 20. Oktober 2025, 00:10 UhrNew compounds halt cancer growth without damaging healthy cells